Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Given the economic conditions in China, Merck withdrew its previously issued long-term guidance of generating more than $11 billion in sales form Gardasil by 2030. Proquad, M-M-R II and Varivax ...